Gemtuzumab ozogamicin in acute myeloid leukemia
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Link
https://www.nature.com/articles/leu2017187.pdf
Reference128 articles.
1. Cowan AJ, Laszlo GS, Estey EH, Walter RB . Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin. Front Biosci (Landmark Ed) 2013; 18: 1311–1334.
2. Macauley MS, Crocker PR, Paulson JC . Siglec-mediated regulation of immune cell function in disease. Nat Rev Immunol 2014; 14: 653–666.
3. Hernández-Caselles T, Martínez-Esparza M, Pérez-Oliva AB, Quintanilla-Cecconi AM, García-Alonso A, Alvarez-López DM et al. A study of CD33 (SIGLEC-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing. J Leukoc Biol 2006; 79: 46–58.
4. Pérez-Oliva AB, Martínez-Esparza M, Vicente-Fernández JJ, Corral-San Miguel R, García-Peñarrubia P, Hernández-Caselles T . Epitope mapping, expression and post-translational modifications of two isoforms of CD33 (CD33M and CD33m) on lymphoid and myeloid human cells. Glycobiology 2011; 21: 757–770.
5. Malik M, Simpson JF, Parikh I, Wilfred BR, Fardo DW, Nelson PT et al. CD33 Alzheimer's risk-altering polymorphism, CD33 expression, and exon 2 splicing. J Neurosci 2013; 33: 13320–13325.
Cited by 178 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A Bayesian pharmacokinetics integrated phase I–II design to optimize dose-schedule regimes;Biostatistics;2024-09-13
2. Targeting the membrane-proximal C2-set domain of CD33 for improved CAR T cell therapy;Molecular Therapy: Oncology;2024-09
3. Unlocking the potential of bispecific ADCs for targeted cancer therapy;Frontiers of Medicine;2024-07-23
4. A dual-targeting approach with anti-IL10R CAR-T cells engineered to release anti-CD33 bispecific antibody in enhancing killing effect on acute myeloid leukemia cells;Cellular Oncology;2024-07-15
5. Immune-inflammatory modulation by natural products derived from edible and medicinal herbs used in Chinese classical prescriptions;Phytomedicine;2024-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3